China Biologic Products Closes the $9.6 Million Private...(rding: the impact ofthe proceeds from th...)

Date:6/11/2009

rding: the impact of the proceeds from the private placement on the business and operations of the Company; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    For more information, please contact:

    Company Contact:

    China Biologic Products, Inc.
     Mr. Y. Tristan Kuo
     Chief Financial Officer
     Tel:   +86-538-6202-206
     Email: IR@chinabiologic.com
     Web:  http://www.chinabiologic.com


    Investor Relations Contact:

    CCG Investor Relations
     Mr. Crocker Coulson, Pr
'/>"/>
SOURCE  China Biologic Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 
Related biology technology :

1. China Biologic Products Enters Into Private Placement Agreements to Raise $9.6 Million
2. Chinas Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation
3. Gerresheimer Opens New High-Tech Production Facility for Pharma Glass in China
4. China-Biotics, Inc. to Attend Digestive Disease Week 2009
5. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
6. China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug
7. The Hamner Institutes Announce Partnership With China Medical City
8. China Sky One Medical, Inc. Appoints Pricewaterhouse Coopers to Help Develop a SOX 404 Compliance Program
9. Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China
10. China Biologic Products Announces Strong First Quarter 2009 Results
11. China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results